Moghaddam A, Zhang H T, Fan T P, Hu D E, Lees V C, Turley H, Fox S B, Gatter K C, Harris A L, Bicknell R
Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, United Kingdom.
Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):998-1002. doi: 10.1073/pnas.92.4.998.
Platelet-derived endothelial cell growth factor was previously identified as the sole angiogenic activity present in platelets; it is now known to be thymidine phosphorylase (TP). The effect of TP on [methyl-3H]thymidine uptake does not arise from de novo DNA synthesis and the molecule is not a growth factor. Despite this, TP is strongly angiogenic in a rat sponge and freeze-injured skin graft model. Neutralizing antibodies and site-directed mutagenesis confirmed that the enzyme activity of TP is a condition for its angiogenic activity. The level of TP was found to be elevated in human breast tumors compared to normal breast tissue (P < 0.001). Overexpression of TP in MCF-7 breast carcinoma cells had no effect on growth in vitro but markedly enhanced tumor growth in vivo. These data and the correlation of expression in tumors with malignancy identify TP as a target for antitumor strategies.
血小板衍生的内皮细胞生长因子先前被鉴定为血小板中存在的唯一血管生成活性物质;现在已知它是胸苷磷酸化酶(TP)。TP对[甲基-3H]胸苷摄取的影响并非源于从头合成DNA,且该分子不是生长因子。尽管如此,在大鼠海绵和冷冻损伤皮肤移植模型中,TP具有很强的血管生成作用。中和抗体和定点诱变证实,TP的酶活性是其血管生成活性的一个条件。与正常乳腺组织相比,人类乳腺肿瘤中TP的水平升高(P < 0.001)。在MCF-7乳腺癌细胞中过表达TP对体外生长没有影响,但显著增强了体内肿瘤生长。这些数据以及肿瘤中表达与恶性程度的相关性将TP确定为抗肿瘤策略的一个靶点。